{
    "clinical_study": {
        "@rank": "11598", 
        "acronym": "IMPROVEII", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "Treatment Period 1: A unit of whole blood is donated and treated with the Mirasol System for Whole Blood; Treatment Period 2: a second unit of whole blood is donated and not treated."
            }, 
            {
                "arm_group_label": "Arm 2", 
                "arm_group_type": "Experimental", 
                "description": "Treatment Period 1: A unit of whole blood is donated and not treated with the Mirasol System for Whole Blood; Treatment Period 2: a second unit of whole blood is donated and treated."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate radiolabeled recovery and survival of autologous\n      red blood cells (RBC), derived from Mirasol-treated fresh whole blood (WB), stored as\n      leukoreduced packed RBC (LR-pRBC), and re-infused in healthy adult subjects"
        }, 
        "brief_title": "Inactivation of Whole Blood With Mirasol", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": "Focus of Study: Radiolabel Recovery and Survival of RBCs", 
        "detailed_description": {
            "textblock": "This is a feasibility level study conducted to assess the recovery and survival of\n      autologous, radiolabeled leukoreduced packed red blood cells (LR-pRBC) derived from fresh\n      whole blood (WB) units that have been treated with the Mirasol System for Whole Blood\n      (Mirasol System) and stored for 21 days at 1-6\u00b0C.1"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Eligible whole blood donor\n\n          -  Age \u2265 18 years, of either sex\n\n          -  Able to commit to the study follow-up schedule\n\n          -  Subjects must have adequate bilateral antecubital venous access for WB collection and\n             follow-up blood draws\n\n          -  Negative screening test panel for infectious diseases\n\n          -  Subjects of child-bearing potential (female or male) must agree to use effective\n             contraceptive during the course of the study per site guidelines\n\n          -  Subjects must agree to report adverse events (AEs) during the required reporting\n             period\n\n          -  Negative direct antiglobulin test (DAT) with subject's RBC\n\n          -  Negative indirect antiglobulin test (IAT) with subject's serum\n\n        Inclusion for radiolabeled reinfusion of LR-pRBC on Day 21 (evaluated the day of, prior\n        to, reinfusion):\n\n          -  Maintenance of healthy status\n\n          -  Negative direct antiglobulin test (DAT) with subject's RBC (fresh)\n\n          -  Negative indirect antiglobulin test (IAT) with subject's serum (fresh) versus\n             autologous stored LR-pRBC\n\n          -  Negative serum or urine pregnancy test in females\n\n        Exclusion Criteria:\n\n          -  Any serious medical illness and/or therapy, including: abnormal bleeding episodes,\n             clotting or bleeding disorder, evidence of anemia, myocardial infarction,\n             uncontrolled hypertension, heart disease, surgery with bleeding complications,\n             epilepsy or any major surgery (with general or spinal anesthesia) within the last 6\n             months\n\n          -  Pregnant or nursing females; For women of childbearing potential, negative serum or\n             urine pregnancy tests at the time of WB donation and before the reinfusion are\n             required\n\n          -  Unable to give informed consent\n\n          -  Participation currently, or within the last 12 months, in another investigational\n             trial that would potentially interfere with the analysis of this investigation (e.g.,\n             pharmaceutical)\n\n          -  Have received an accumulated radiation dose that would exclude them from the study\n             according to the local radiation safety limits established by each institution\n\n          -  Inability to comply with the protocol in the opinion of the investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "29", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01907906", 
            "org_study_id": "CTS-0080", 
            "secondary_id": "ERMS#12308001"
        }, 
        "intervention": {
            "arm_group_label": [
                "Arm 1", 
                "Arm 2"
            ], 
            "description": "LR-pRBC units derived from WB will be treated with the Mirasol System.  Treatment with the Mirasol System requires riboflavin to be mixed into the whole blood unit, which is then exposed to UV light for a period of time; approximately an hour.", 
            "intervention_name": "Mirasol System for Whole Blood", 
            "intervention_type": "Device", 
            "other_name": "Pathogen Reduction Technology"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Pathogen reduction technology", 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45267"
                    }, 
                    "name": "Hoxworth Blood Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98104"
                    }, 
                    "name": "Puget Sound Blood Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Inactivation of Whole Blood With Mirasol : Performance in Red Blood Cells in Healthy Volunteers", 
        "other_outcome": {
            "description": "Data will be collected to: 1.) Evaluate RBC survival, half-life, and area under the curve (AUC); 2.) Determine incidence of neoantigenicity; 3.) Determine in vitro characteristics of test and control RBC; 4.) Determine incidence of adverse events (AEs); and 4.) Evaluate correlations identified in the initial IMPROVE Trial as predictive models (24-hour red blood cell (RBC) recovery and half-life with % hemolysis, adenosine triphosphate (ATP), and carbon dioxide partial pressure [pCO2]).", 
            "measure": "Other Data Collection", 
            "safety_issue": "Yes", 
            "time_frame": "168 days"
        }, 
        "overall_official": {
            "affiliation": "TerumoBCT Biotechnologies", 
            "last_name": "Raymond P Goodrich, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Federal Government", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To evaluate, as per FDA criteria, the 24-hour post transfusion RBC recovery in healthy adult subjects of LR-pRBC that have been derived from Mirasol-treated fresh WB units and stored at 1 to 6\u00b0C for 21 days.", 
            "measure": "Red Blood Cell Recovery", 
            "safety_issue": "No", 
            "time_frame": "24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01907906"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Terumo BCTbio", 
        "sponsors": {
            "collaborator": {
                "agency": "U.S. Army Medical Research and Materiel Command", 
                "agency_class": "U.S. Fed"
            }, 
            "lead_sponsor": {
                "agency": "Terumo BCTbio", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}